B
Bullisch
Bullisch · 25%ECOR
$6.71
Szenariopreis
$8.800
+0.419 (+4.76%)Zum Schluss
Loading chart…
- Hoch
- 9.000
- Eröffnung
- 8.120
- Volumengewichteter Durchschnittskurs
- 8.56
- Volumen
- 185.65K
- Marktkap.
- 41.50M
- Tief
- 7.895
- Umsatz
- 1.59M
- EV/EBITDA, TTM
- -5.64
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
KI-Analyse of electroCore, Inc. (ECOR)
VerkaufenCurrently, electroCore, Inc. (ECOR) is not a good buy. The stock is trading at $7.16, which is significantly below its 52-week high of $12.70, indicating a potential for further downside. Additionally, the RSI is at 33.004, suggesting that the stock is oversold, but this could also mean continued weakness in the short term. The forward P/E ratio is extremely high at 384.6154, reflecting investor skepticism about future earnings growth, while insider selling has increased by 666.36% over the last month, indicating a lack of confidence from those closest to the company. The main risk is the negative earnings trend, with an EPS estimate of -0.26 for the next earnings report, which could further pressure the stock price.
Analystenbewertungen (2)
+70.45% Aufwärtspotenzial
Kaufen
2 Kaufen
0 Halten
0 Verkaufen
Aktuell: 8.80
Tief
12.00
Durchschnitt
15.00
Hoch
18.00
Ladenburg
Kaufen
—
2026-11-05
Ladenburg
2026-11-05
Kursziel
—
Kaufen
Ladenburg
Kaufen
$22
2026-05-07
Ladenburg
2026-05-07
Kursziel
$22
Kaufen
H.C. Wainwright
Kaufen
$18
2026-01-26
H.C. Wainwright
2026-01-26
Kursziel
$18
Kaufen
Ladenburg Thalmann
Starker Kauf
$26
2025-03-13
Ladenburg Thalmann
2025-03-13
Kursziel
$26
Starker Kauf
HC Wainwright & Co.
Starker Kauf
$25
2025-03-13
HC Wainwright & Co.
2025-03-13
Kursziel
$25
Starker Kauf
Bewertungskennzahlen
Das aktuelle erwartete KGV von electroCore, Inc. (ECOR) beträgt 384.62, verglichen mit dem 5-Jahres-Durchschnitt von 63.56.
Alphio-AI-Kursszenarien für ECOR
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die ECOR halten
Event-Zeitleiste
News
9.010-28NewsfilterelectroCore Submits 510(k) for Quell Device to Treat CIPN
2.009-07Yahoo FinanceEcora Announces Change of Registered Office Address
9.509-04Yahoo FinanceEcora Reports 75% Increase in H1 2026 Portfolio Contribution
9.509-02Yahoo FinanceEcora Royalties Reports Strong Half-Year Results for 2026
2.005-27NASDAQ.COMMultiple Companies See Significant Stock Price Gains
ECOR FAQ – beantwortet von Alphio AI
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
Currently, electroCore, Inc. (ECOR) is not a good buy. The stock is trading at $7.16, which is significantly below its 52-week high of $12.70, indicating a potential for further downside. Additionally, the RSI is at 33.004, suggesting that the stock is oversold, but this could also mean continued weakness in the short term. The forward P/E ratio is extremely high at 384.6154, reflecting investor skepticism about future earnings growth, while insider selling has increased by 666.36% over the last month, indicating a lack of confidence from those closest to the company. The main risk is the negative earnings trend, with an EPS estimate of -0.26 for the next earnings report, which could further pressure the stock price.
2 analysts cover ECOR: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.00.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.